年龄对德国银屑病医疗的影响
基于德国PsoBest注册研究中3615例接受系统治疗的中重度银屑病或银屑病关节炎成人患者,分析年龄组间银屑病特征差异及其对医疗的影响。结果显示,生物制剂在年轻患者中使用显著较少(16.2%),而中年患者银屑病关节炎和甲银屑病发生率更高,可能解释年龄相关的医疗差异。
要点
- 年轻患者(18-34岁)生物制剂使用率显著低于中年和老年组。
- 中年患者(35-64岁)银屑病关节炎和甲银屑病发生率更高。
- 红皮病型银屑病在老年患者中更常见。
核心结论
- 中年患者银屑病关节炎和甲银屑病发生率更高,可能解释包括系统治疗使用在内的年龄相关医疗差异。
研究设计与样本
- 对德国银屑病注册研究PsoBest中3615例接受系统治疗的中重度银屑病或银屑病关节炎成人患者进行10年观察的数据分析。
主要发现
- 红皮病型银屑病在老年患者中比35-64岁组更常见(1.9%,P ≤ 0.048)。
- 甲银屑病在35-64岁组显著更常见(55.5%,P ≤ 0.001),且受累甲数最多(6.9 ± 3.3)。
- 银屑病关节炎在18-34岁组较少见(9.5%,P ≤ 0.001)。
- 18-34岁组头皮银屑病发生率最高(85.8%),显著高于老年组(P ≤ 0.001)。
- 生物制剂在年轻患者中使用显著较少(16.2%),低于35-64岁组(23.9%,P ≤ 0.001)和65岁以上组(21.8%,P ≤ 0.042)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Inequality between age groups has been demonstrated in the prescription of biologics, yet systematic real-world data about age-related differences in psoriasis care are missing. OBJECTIVE: To investigate disparities in psoriasis characteristics by age groups and to identify potential impact on psoriasis health care. PATIENTS AND METHODS: Data analysis included 3615 patients from the German psoriasis registry PsoBest, which observes adult patients with moderate-to-severe psoriasis or psoriatic arthritis (PsA) on systemic treatment over a time period of 10 years. RESULTS: With 2376 participants (65.7%), the majority of patients was assigned to the age group 35-64, followed by 776 (21.4%) and 463 (12.8%) for the age groups 18-34 and 65+, respectively. Psoriasis vulgaris was the most frequent form of psoriasis with nearly 90% patients affected. Appearance of psoriasis forms did not differentiate significantly between the age groups except for erythrodermic psoriasis, which was more frequent in the elderly than in patients aged 35-64 (1.9%, P ≤ 0.048). Nail psoriasis appeared significantly more often in patients aged 35-64 (55.5%, P ≤ 0.001) and also showed the highest number of nails involved (6.9 ± 3.3). PsA was less frequent in the age group 18-34 (9.5%, P ≤ 0.001). This group showed the highest rate of scalp psoriasis (85.8%) compared to the elder age groups (P ≤ 0.001). Biologicals were used significantly less in younger patients (16.2%) compared to the age groups 35-64 (23.9%, P ≤ 0.001) and 65+ (21.8%, P ≤ 0.042). CONCLUSION: Middle-aged patients show higher rates of PsA and nail psoriasis, which may explain age-dependent disparities in health care including the use of systemic treatment.
引用
- Trettel A, Spehr C, Körber A, et al. The impact of age on psoriasis health care in Germany. J Eur Acad Dermatol Venereol. 2017. PMID: 28079929. doi:10.1111/jdv.14115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。